Apr 01, 2015
Cadwalader represented Salix Pharmaceuticals, Ltd., a leading U.S. specialty pharmaceutical company, in its acquisition by Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) for $173.00 per share, or a total enterprise value of approximately $15.6 billion. The transaction was completed on April 1, 2015.
Cadwalader has advised Salix in connection with various governance, litigation and transactional matters, including its terminated combination with Cosmo Technologies.
The Cadwalader team is led by partner and Chair of the Corporate Group, Christopher Cox, and includes Corporate partners Gregory Patti, Jr., William Mills and Ira Schacter, Corporate special counsel Andrew Alin, and Corporate associates Anita Wong and Alexandra Cotter, in New York; Antitrust partners Rick Rule and Andrew Forman in Washington, DC. and special counsel Anne MacGregor in Brussels; Tax partner Linda Swartz and special counsel Edward Wei in New York; Intellectual Property partner Dorothy Auth in New York; Finance partner Jeff Nagle in Charlotte; and Litigation partner Martin Seidel in New York.
Cadwalader, Wickersham & Taft LLP, established in 1792, serves a diverse client base, including many of the world's leading financial institutions and corporations in more than 50 countries. With offices in New York, London, Charlotte, Washington, Houston, Beijing, Hong Kong and Brussels, Cadwalader offers legal expertise in antitrust, banking, corporate finance, corporate governance, energy, environmental, executive compensation, financial restructuring, health care, intellectual property, litigation, mergers and acquisitions, private equity, private wealth, real estate, regulation, securitization, structured finance, tax and white collar defense. For more information, visit www.cadwalader.com.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license or acquire late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through Salix’s 500-member specialty sales force.
September 3 Issue
On 13 September, the EBA updated its guidance in respect of the Securitisation Regulation.